Aerie Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc 21.95%75.366.5%$147.38m
VRXValeant Pharmaceuticals International, Inc. 1.98%19.3714.1%$113.98m
CTLTCatalent, Inc. 1.67%89.662.1%$94.55m
BHCBausch Health Cos., Inc. 1.99%19.370.0%$64.85m
JAZZJazz Pharmaceuticals Plc 10.36%121.932.4%$64.61m
TNXPTonix Pharmaceuticals Holding Corp. 5.79%1.283.9%$63.68m
ARGXargenx SE 0.77%233.390.0%$46.97m
PCRXPacira Biosciences, Inc. 1.72%56.2310.3%$44.65m
ICLRICON plc 1.71%190.284.3%$42.55m
UTHRUnited Therapeutics Corp. -0.68%113.3114.1%$42.19m
ICPTIntercept Pharmaceuticals, Inc. 0.04%47.6016.8%$41.47m
PRGOPerrigo Co. Plc -5.06%52.336.8%$40.16m
GWPHGW Pharmaceuticals Plc -0.44%134.776.2%$37.99m
MYOKMyoKardia, Inc. 1.35%99.321.8%$36.53m
AMRNAmarin Corp. Plc -3.91%6.761.5%$35.89m

Company Profile

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.